Related Experiment Videos
C-reactive protein: a novel marker of cardiovascular risk
Svati H Shah1, L Kristin Newby
1Department of Cardiology, Duke University Medical Center, Durham, North Carolina, USA.
Insights
High-sensitivity C-reactive protein (hs-CRP) is a key inflammatory biomarker for predicting cardiovascular events. Elevated hs-CRP levels identify individuals at higher risk, improving cardiovascular risk assessment beyond traditional factors.
Area of Science:
- Biochemistry
- Cardiology
- Immunology
Background:
- Cardiovascular events occur in patients lacking traditional risk factors, necessitating novel risk assessment markers.
- Inflammation plays a crucial role in atherosclerosis, making inflammatory biomarkers prime candidates for risk prediction.
Purpose of the Study:
- To review the role of C-reactive protein (CRP) measurements in cardiovascular risk assessment.
- To highlight the utility of high-sensitivity CRP (hs-CRP) assays in identifying at-risk individuals.
Main Methods:
- Review of existing studies on CRP levels and cardiovascular events.
- Analysis of CRP's predictive value in primary prevention and established cardiovascular disease populations.
- Evaluation of hs-CRP assays for enhanced sensitivity and reproducibility.
Main Results:
- Elevated CRP levels indicate a 2-4 fold increased risk of cardiovascular events in primary prevention populations.
- Models combining CRP and lipid parameters offer superior risk prediction compared to lipids alone.
- CRP levels aid in predicting prognosis for patients with established cardiovascular disease and post-intervention.
Conclusions:
- CRP is a powerful predictor of cardiovascular risk across diverse patient groups.
- hs-CRP measurements enhance cardiovascular risk stratification and may guide therapeutic interventions.
- CRP assessment can identify patients who would benefit most from preventive therapies like statins and aspirin.
Abstract:
Patients without traditional cardiovascular risk factors continue to suffer from cardiovascular events, which has prompted a search for novel markers to better assess cardiovascular risk. Inflammatory biomarkers have surfaced as prime candidates, given the integral role of inflammation in atherosclerosis. C-reactive protein (CRP) measurements in particular have emerged as powerful predictors of cardiovascular risk in a broad spectrum of patient populations. Newer high sensitivity CRP assays now in use are standardized and reproducible, and can detect variations in CRP below the limit of standard assays. In primary prevention populations, studies have shown up to a 2-4-fold increased risk of cardiovascular events in healthy patients with elevated CRP levels. In this population, models incorporating CRP and lipid parameters appear to predict risk significantly better than lipids alone. In patients with established cardiovascular disease and in patients undergoing percutaneous coronary interventions, CRP levels may help predict short- and long-term prognosis, identifying subgroups of patients at increased risk of recurrent events. CRP levels may also prove useful in targeting therapy for primary and secondary prevention, by identifying patients who would most benefit from medications such as statins and aspirin. This review presents an overview of the data regarding CRP measurement for cardiovascular risk assessment.